Member Posts > How Cardiol Therapeutics' CRD-38 Could Shift the Paradigm in HF Treatment
Traditional heart failure (HF) treatments focus on symptom management rather than addressing the underlying cellular dysfunction that drives disease progression. Mitochondrial dysfunction is one of the root causes of HF, leading to decreased ATP production, increased oxidative stress, and progressive heart failure. Cardiol Therapeutics' CRD-38 offers a paradigm shift in treatment by specifically targeting mitochondrial dysfunction. This subcutaneous cannabidiol-based therapy leverages CBD's anti-inflammatory effects to mitigate oxidative stress while simultaneously activating PPAR-γ to stimulate mitochondrial biogenesis and improve energy efficiency. Preclinical studies highlight CRD-38's ability to enhance mitochondrial respiration, reduce oxidative damage, and support overall heart function. Given the high prevalence of metabolic inefficiencies in HFpEF patients, CRD-38 could emerge as a transformative therapy. As Cardiol Therapeutics moves forward with regulatory processes, CRD-38 is positioned to redefine HF treatment by addressing mitochondrial health at its core.

#CardiolTherapeutics #HeartFailureTreatment #BiotechInvesting #ClinicalTrials #CBDTherapeutics #HeartHealth #MedicalInnovation #PharmaceuticalBreakthroughs #CRD38